As of 2025-12-14, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,478.19 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 39.5x - 64.5x | 63.4x |
| Forward P/E multiples | 39.5x - 68.1x | 63.4x |
| Fair Price | (26.79) - (44.47) | (43.68) |
| Upside | -214.8% - -290.6% | -287.2% |
| Date | EV/EBITDA |